Mersana Therapeutics Inc (MRSN) Reports Fourth Quarter and Full Year 2023 Financial Results [Yahoo! Finance]
Mersana Therapeutics, Inc. (MRSN)
Last mersana therapeutics, inc. earnings: 2/28 06:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
mersana.com/about-mersana
Company Research
Source: Yahoo! Finance
Revenue : Fourth quarter collaboration revenue was $10.7 million, contributing to a total of $36.9 million for the full year. Operating Expenses : Research and development expenses were $21.5 million for the quarter and $148.3 million for the year. Net Loss : Mersana reported a net loss of $19.5 million for the quarter and $171.7 million for the full year. Earnings Per Share : Net loss per share was $0.16 for the quarter and $1.48 for the full year. Warning! GuruFocus has detected 7 Warning Signs with MRSN. Mersana Therapeutics Inc ( NASDAQ:MRSN ) released its 8-K filing on February 28, 2024, providing a business update and announcing its financial results for the fourth quarter and full year ended December 31, 2023. The clinical-stage biopharmaceutical company, which specializes in antibody-drug conjugates (ADCs) for cancer treatment, reported a year-end cash position of $209.1 million and a net loss of $19.5 million for the quarter. Despite the net loss, the company highl
Show less
Read more
Impact Snapshot
Event Time:
MRSN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MRSN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MRSN alerts
High impacting Mersana Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
MRSN
News
- Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Mersana Therapeutics to Host First Quarter 2024 Conference Call on May 9, 2024GlobeNewswire
- Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Mersana Therapeutics, Inc. (NASDAQ: MRSN) was upgraded by analysts at JPMorgan Chase & Co. from an "underweight" rating to a "neutral" rating. They now have a $5.00 price target on the stock.MarketBeat
- AVLX, SGH and ETNB are among pre market losers [Seeking Alpha]Seeking Alpha
MRSN
Earnings
- 2/28/24 - Beat
MRSN
Sec Filings
- 4/26/24 - Form ARS
- 4/26/24 - Form DEFA14A
- 4/26/24 - Form DEF
- MRSN's page on the SEC website